A double-blind, randomized controlled clinical study: gatifloxacin vs levofloxacin in treatment of 98 patients with urinary tract infections
Abstract
AIM:To evaluate the safety and efficacy of domestic gatifloxacin in the treatment of urinary tract infections. METHODS:A multicenter,double-blind,randomized control clinical trial of gatifloxacin and levofloxacin was conducted. Both two groups were treated with gatifloxacin or levofloxacin 200 mg,iv, gtt,bid,for 7-14 d. RESULTS: The patients enrolled into gatifloxacin group and levofloxacin group in the double-blind study were 48,50 respectively. The patients for the efficacy analysis were 47,50 respectively. The overall cured rate,efficacy rate and bacterial clearance rate in trial group were 89 %,100 %,89 % respectively and those in control group were 90 %,96 %,85 % respectively. The activities of gatifloxacin against gram-positive organisms in vitro were generally higher than those of the other antibacterial agents. The adverse reaction rate was 10 %and 12 % in trial and control group respectively. There were no statistical significant differences in the above results between the two groups(P0.05). CONCLUSION: The results suggest that demostic gatifloxacin is highly effective and safe in the treatment of urinary tract infections.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.